Chemotherapy, surgery and radiotherapy are USFDA-approved treatments that have long been used as primary and secondary treatments for cancer.
However, when cancer recurs in the future, or when these primary and secondary treatments are unable to reduce or kill cancer, then doctors and patients may opt for other types of treatments including immunotherapy and also drugs that are still undergoing clinical trials nearing FDA approval. The clinical outcomes of CAR T-Cell Immunotherapy have been impressive and have shown remarkable results in relapsed/refractory cancer patients.
